Debdulal Chakraborty
YOU?
Author Swipe
View article: Biosimilar Versus Innovator Ranibizumab in Myopic CNVM: Comparative Real-World Outcomes- The BRIM Study
Biosimilar Versus Innovator Ranibizumab in Myopic CNVM: Comparative Real-World Outcomes- The BRIM Study Open
Biosimilar ranibizumab demonstrated non-inferior visual and anatomical outcomes compared to innovator ranibizumab in the treatment of mCNVM, with a similar safety profile and treatment burden.
View article: Authors’ response: “Brolucizumab-associated intraocular inflammation in Indian patients by VRSI study group”
Authors’ response: “Brolucizumab-associated intraocular inflammation in Indian patients by VRSI study group” Open
View article: Safety and effectiveness of brolucizumab in patients with neovascular age-related macular degeneration: A phase IV study from India
Safety and effectiveness of brolucizumab in patients with neovascular age-related macular degeneration: A phase IV study from India Open
Purpose: The purpose of this study is to evaluate the safety and effectiveness of brolucizumab intravitreal injections (IVI) in Indian patients with neovascular age-related macular degeneration (nAMD). Methods: This prospective, interventi…
View article: CompaRative Safety Analysis of Innovator and BioSimilar Ranibizumab in Chorioretinal Vascular Diseases - The CRsIBS Study
CompaRative Safety Analysis of Innovator and BioSimilar Ranibizumab in Chorioretinal Vascular Diseases - The CRsIBS Study Open
This large-scale real-world study demonstrates that biosimilar ranibizumab offers a comparable safety profile to innovator ranibizumab in the management of chorioretinal vascular diseases. The affordability of biosimilar ranibizumab enhanc…
View article: A Study on Repurposing of Antibiotic Drugs for Human MMPs Enzyme: A Possible Hope for Arthritis Drug
A Study on Repurposing of Antibiotic Drugs for Human MMPs Enzyme: A Possible Hope for Arthritis Drug Open
Arthritis is a prevalent condition that primarily affects elderly individuals, especially women. Matrix Metallo proteinases (MMPs), specifically types 1,2,3,9 and 13are key players in the progression of arthritis and represent promising dr…
View article: Biosimilar Ranibizumab (Ranieyes) Safety and Efficacy in the Real World: BRESER Study
Biosimilar Ranibizumab (Ranieyes) Safety and Efficacy in the Real World: BRESER Study Open
Purpose: To evaluate the early real-world clinical outcomes regarding the safety and efficacy after administration of a ranibizumab biosimilar (Ranieyes). Methods: This multicenter retrospective uncontrolled observational study incorporate…
View article: Innovator ranibizumab ComparEd to Biosimilar ranibizumab in combination with Expansile gas in submaculaR HemorrhaGe: the ICEBERG study
Innovator ranibizumab ComparEd to Biosimilar ranibizumab in combination with Expansile gas in submaculaR HemorrhaGe: the ICEBERG study Open
Biosimilar RBZ may act as a viable alternative to innovator RBZ to treat SMH with comparable anatomical and visual outcomes at 6 months.
View article: Clinical Evaluation of Faricimab in Real-World Diabetic Macular Edema in India- A Multicenter Observational Study
Clinical Evaluation of Faricimab in Real-World Diabetic Macular Edema in India- A Multicenter Observational Study Open
Faricimab treatment resulted in significant improvements in visual acuity and anatomical outcomes in both treatment-naïve and recalcitrant DME eyes, highlighting its potential as a valuable therapeutic option in diverse clinical settings. …
View article: Cavitand-Mediated Photodimerization of Chalcones: Effect of Supramolecular Influences and External Factors on Reaction Selectivity
Cavitand-Mediated Photodimerization of Chalcones: Effect of Supramolecular Influences and External Factors on Reaction Selectivity Open
View article: Pooled Multicenter Safety Analysis of Lupin’s Intravitreal Biosimilar Ranibizumab (Ranieyes) in Chorioretinal Vascular Diseases
Pooled Multicenter Safety Analysis of Lupin’s Intravitreal Biosimilar Ranibizumab (Ranieyes) in Chorioretinal Vascular Diseases Open
This large-scale, real-world study demonstrates that Ranieyes is a safe intravitreal antivascular endothelial growth factor (anti-VEGF) agent across various chorioretinal vascular diseases. The safety profile of Ranieyes is consistent with…
View article: Transitioning from Aflibercept to Biosimilar Ranibizumab in Diabetic Macular Edema (DME): (The TRANSFORM-DME Trial) a Multicenter Observational Study
Transitioning from Aflibercept to Biosimilar Ranibizumab in Diabetic Macular Edema (DME): (The TRANSFORM-DME Trial) a Multicenter Observational Study Open
Transitioning to biosimilar Ranibizumab (Razumab) after initial treatment with aflibercept in patients with DME preserved visual and anatomical benefits over a 12-month period, with only minor variations in SRF and IRF. These results under…
View article: Brolucizumab versus aflibercept for recalcitrant diabetic macular edema in Indian real-world scenario – The BRADIR study
Brolucizumab versus aflibercept for recalcitrant diabetic macular edema in Indian real-world scenario – The BRADIR study Open
The BRADIR study suggests that brolucizumab might have an edge over aflibercept in visual and anatomical outcomes that lasted 52 weeks with reduced injection frequency in case of recalcitrant DME.
View article: Brolucizumab-associated intraocular inflammation in Indian patients by VRSI study group
Brolucizumab-associated intraocular inflammation in Indian patients by VRSI study group Open
Context: Concerns about brolucizumab’s (Pagenax ® ) association with intraocular inflammation (IOI) limit its use despite its cost-effectiveness and efficacy. This multicentric study analyzes IOI incidence across 21 tertiary eyecare center…
View article: Transitioning from Aflibercept to Biosimilar Ranibizumab in Neovascular AMD (The TRANSFORM Trial): A Multicenter Observational Study
Transitioning from Aflibercept to Biosimilar Ranibizumab in Neovascular AMD (The TRANSFORM Trial): A Multicenter Observational Study Open
The switch from IVI AFL to IVI B-RBZ in patients with nAMD demonstrated efficacy in maintaining the VA and macular anatomy, with some challenges in fluid management.
View article: Efficacy and safety of large-scale use of vancomycin injection in infusion bottle during vitreoretinal procedures
Efficacy and safety of large-scale use of vancomycin injection in infusion bottle during vitreoretinal procedures Open
PURPOSE: The purpose of this study was to assess the safety and efficacy of large-scale use of vancomycin injection in an infusion bottle during vitreoretinal procedures. MATERIALS AND METHODS: This was a retrospective evaluation of all vi…
View article: Aflibercept vs. dexamethasone implant for recalcitrant diabetic macular edema in pseudophakic eyes – 1-year outcomes from a quazi-randomized study in India
Aflibercept vs. dexamethasone implant for recalcitrant diabetic macular edema in pseudophakic eyes – 1-year outcomes from a quazi-randomized study in India Open
Purpose: To assess the safety and efficacy of intravitreal Aflibercept (IVA) versus dexamethasone (DEX) implant for treating recalcitrant diabetic macular edema (DME) in pseudophakic eyes at 1-year follow-up. Design: Retrospective comparat…
View article: Retained cotton fiber in a silicone oil–filled vitrectomized eye
Retained cotton fiber in a silicone oil–filled vitrectomized eye Open
Intraocular foreign bodies (IOFB) are common with ocular trauma, surgery, and intraocular injections.[1] The incidence of anterior chamber (AC) cotton fiber following uneventful cataract surgery is 0.78%–1.7%.[2] Cotton -tipped applicator …
View article: Intraocular caterpillar hair, twenty years and more
Intraocular caterpillar hair, twenty years and more Open
A 26 years old female patient presented with redness and pain in her right eye (RE). Her best-corrected visual acuity (BCVA) was 20/40 in the RE and 20/20 in the left eye (LE). On slit-lamp examination, her RE showed circumciliary congesti…
View article: A rare case of very late recurrence of CSCR-induced CNVM following intra-articular injection of depot steroid
A rare case of very late recurrence of CSCR-induced CNVM following intra-articular injection of depot steroid Open
Choroidal neovascular membrane (CNVM) is a major cause of long-term vision loss in patients with chronic central serous chorioretinopathy (CSCR). External steroid medications, both oral and injectable, have long been proven as one of the m…
View article: Novel surgical technique for macular holes with basal diameter >1000 μ
Novel surgical technique for macular holes with basal diameter >1000 μ Open
Closure rate of full-thickness macular holes (FTMHs) with basal diameter >1000 μ is known to be poor. Patients presenting with FTMH having a minimum basal diameter of >1000 μ without any coexistent retinal morbidity were offered vitrectomy…
View article: Commentary on ‘Optical coherence tomography angiography parameters in patients taking hydroxychloroquine therapy – cross-sectional study’
Commentary on ‘Optical coherence tomography angiography parameters in patients taking hydroxychloroquine therapy – cross-sectional study’ Open
View article: Commentary on ‘Attitude and perception toward clinical trials in India among patients and patient bystanders visiting Indian ophthalmology clinical trial network: A multicentric, cross-sectional survey’
Commentary on ‘Attitude and perception toward clinical trials in India among patients and patient bystanders visiting Indian ophthalmology clinical trial network: A multicentric, cross-sectional survey’ Open
View article: Short-Term Treatment Outcomes of Brolucizumab in Patients with Neovascular Age-Related Macular Degeneration: A Multicentre Indian Real-World Evidence Study
Short-Term Treatment Outcomes of Brolucizumab in Patients with Neovascular Age-Related Macular Degeneration: A Multicentre Indian Real-World Evidence Study Open
The study reports on the short-term effectiveness and tolerability of brolucizumab therapy in the management of nAMD in both treatment-naïve and switch eyes. Brolucizumab was observed to have a favourable benefit-risk profile, and study re…
View article: Incidence, clinical features, risk factors, and outcomes of Intraocular inflammation following Brolucizumab in Indian eyes – A multicentric study
Incidence, clinical features, risk factors, and outcomes of Intraocular inflammation following Brolucizumab in Indian eyes – A multicentric study Open
Purpose: To report the incidence, clinical features, potential risk factors, and outcomes of intraocular inflammation (IOI) following brolucizumab in Indian eyes. Methods: All consecutive patients diagnosed with brolucizumab-induced IOI fr…
View article: Real-world outcomes and complications of different surgical approaches for significant submacular haemorrhages
Real-world outcomes and complications of different surgical approaches for significant submacular haemorrhages Open
Purpose: To evaluate the outcomes and complications after different surgical management of cases with significant sumacular hemorrhage (SMH) of size more than 4 disc diameter (DD). Methods: It was a retrospective interventional study. All …
View article: Variable response of sub-retinal hyper-reflective membranes to anti-vascular endothelial growth factor treatment in bilateral neo-vascular age-related macular degeneration
Variable response of sub-retinal hyper-reflective membranes to anti-vascular endothelial growth factor treatment in bilateral neo-vascular age-related macular degeneration Open
Sub-retinal hyper-reflective material (SHRM) is an important spectral-domain optical coherence tomography biomarker in neo-vascular age-related macular degeneration (nAMD). The exact nature of SHRM is not known, but it may contain fluid, f…
View article: Biosimilar versus InnovAtor MoLecule of RAnibizumab in Neovascular Age-Related MaCular DEgeneration (The BALANCE Trial): Real-World Evidence
Biosimilar versus InnovAtor MoLecule of RAnibizumab in Neovascular Age-Related MaCular DEgeneration (The BALANCE Trial): Real-World Evidence Open
Intravitreal injection of IRM and BRM show similar efficacy and safety in Indian eyes with nAMD.
View article: Commentary: Clinical profile, demographic distribution, and outcomes of ocular siderosis: Electronic medical record-driven big data analytics from an eye care network in India
Commentary: Clinical profile, demographic distribution, and outcomes of ocular siderosis: Electronic medical record-driven big data analytics from an eye care network in India Open
First described in 1890 by Bunge, ocular siderosis (OS) occurs due to a retained ferrous intraocular foreign body (IOFB) that causes iron deposition in the ocular tissues.[1] OS may develop from 18 days to years after a penetrating ocular …
View article: Ultrawide-field imaging of bilateral retinoblastoma in an infant by “flying baby position”
Ultrawide-field imaging of bilateral retinoblastoma in an infant by “flying baby position” Open
A 3-month-old male baby with white pupillary reflex in the left eye underwent ultrawide-field (UWF) imaging using UWF Optos camera (Optos, Dunfermline, UK) following indirect ophthalmoscopic examination with a strong clinical suspicion of …
View article: Assessing Smell Alteration as Clinical Feature of COVID-19: A Descriptive Study in a Rural Based Tertiary Care COVID Hospital
Assessing Smell Alteration as Clinical Feature of COVID-19: A Descriptive Study in a Rural Based Tertiary Care COVID Hospital Open
Introduction COVID-19 is an ongoing viral pandemic and a very contagious disease. Other than common symptoms like fever, cough and malaise; alteration in smell and taste perception may be the presenting symptoms in a significant number of …